SEC ownership of Guardian Pharmacy Services, Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001802255.

Comparable stake leader

Bindley Capital Partners I, LLC

Disclosed value leader

Bindley Capital Partners I, LLC

Comparable rows

50/50

Latest evidence

05 May 2026

Top shareholders Insider holders Latest transactions
Public ticker
GRDN on NYSE
Parsed ownership sources
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
Largest SEC-reported holder
Bindley Capital Partners I, LLC
Ranking: Comparable ownership first, then disclosed value
Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
50 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
Bindley Capital Partners I, LLC
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
05 May 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001802255
Issuer location
Atlanta, GA

Ownership snapshot

Top shareholders of Guardian Pharmacy Services, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Bindley Capital Partners ...
Disclosed value leader
Bindley Capital Partners ...
Comparable rows
50/50
Latest evidence
05 May 2026
13D/G 3/4/5 13F Lead comparable stake: 21% 13D/G row: Bindley Capital Partners I, LLC Showing 1-8 of 50 holder rows.

Quick read

Bindley Capital Partners I, LLC leads the comparable SEC ownership view at 21%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Bindley Capital Partners I, LLC's linked filing trail.
Comparable ownership Top 5
Bindley Capital Partners I, LLC 21%
FMR LLC 6.5%
Alyeska Investment Group, L.P. 4.7%
BROWN ADVISORY INC 4.5%
Woodline Partners LP 4.5%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Bindley Capital Partners I, LLC
13D/G 3/4/5
Thomas J. Salentine, Jr. · 10%+ Owner
13D/G 3/4/5
21%
$350,077,817
10,605,205 shares
 +$83,498,729 20 Mar 2026
FMR LLC
13D/G 13F
Company
13D/G 13F
6.5%
$92,368,815
2,359,357 shares
 $0 31 Mar 2026
Alyeska Investment Group, L.P.
13F 13D/G
Company
13F 13D/G
4.7%
from 13D/G
$10,356,500
275,000 shares
 — 31 Mar 2026
BROWN ADVISORY INC
13D/G 13F
Company
13D/G 13F
4.5%
$49,485,081
1,644,569 shares
 +$1,116,399 31 Dec 2025
Woodline Partners LP
13F 13D/G
Company
13F 13D/G
4.5%
from 13D/G
$49,195,936
1,306,318 shares
 — 31 Mar 2026
FRANKLIN RESOURCES INC
13F 13D/G
Company
13F 13D/G
4.3%
from 13D/G
$35,888,172
952,952 shares
 — 31 Mar 2026
VANGUARD GROUP INC
13D/G
The Vanguard Group
13D/G
4.2%
$20,602,636
966,806 shares
 +$7,853,289 30 Jun 2025
BlackRock, Inc.
13F 13D/G
Company
13F 13D/G
4.2%
from 13D/G
$66,145,045
1,756,374 shares
 — 31 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to selling over the last 12 months. Net value: -$419,157,156.

Buys
$99,786
Insiders: 1
Sells
$419,256,942
Insiders: 9
Net
-$419,157,156
Shares: -14,121,348
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 3,370 Shares: 14,124,718
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 0 14,124,718 $0 $419,256,942 -$419,256,942
6-9 3,370 0 $99,786 $0 +$99,786
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-19 of 19 reporting-owner rows connected to Guardian Pharmacy Services, Inc.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
19
Largest Forms 3/4/5 holder
Thomas J. Salentine Jr.
Net 12M change
-$419,157,156
Latest report
05 May 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Thomas J. Salentine Jr. Director, 10%+ Owner $707,447,780 -$105,986,620 -13% Mixed 28 Mar 2026
William E. Bindley Director, 10%+ Owner $706,373,146 -$105,986,620 -13% Mixed 28 Mar 2026
Bindley Capital Partners I, LLC 10%+ Owner $318,035,984 -$105,986,620 -25% Mixed 28 Mar 2026
John Ackerman Director $218,274,221 -$32,750,602 -13% Mixed 28 Mar 2026
Fred Burke President and Chief Executive Officer, Director $147,052,943 -$19,929,780 -12% Mixed 28 Mar 2026
Pharmacy Investors, LLC Member of 10% owner group $73,716,498 -$24,566,306 -25% Mixed 28 Mar 2026
Kendall Forbes Executive Vice President, Sales & Operations $70,691,910 -$10,290,092 -13% Mixed 28 Mar 2026
David K. Morris Executive Vice President and Chief Financial Officer, Director $67,832,302 -$5,576,006 -7.6% Mixed 28 Mar 2026
Cardinal Equity Fund, L.P. Member of 10% owner group $24,558,856 -$8,184,296 -25% Mixed 28 Mar 2026
Jeffrey Tuch Senior Vice President, Purchasing & Pricing Analytics Exhibit 24.1 - Power of Attorney $6,633,584 Mixed 01 Apr 2026
David Norman Martin Senior Vice President, Technology, Data & Senior Security Officer Exhibit 24.1 - Power of Attorney $3,802,468 Mixed 01 Apr 2026
Richard Eakins Senior Vice President, Sales $3,721,105 Mixed 01 Apr 2026
William Franklin Mudd Senior Vice President, Finance $3,705,562 Mixed 01 Apr 2026
Douglas Towns Officer $3,370,287 Mixed 01 Apr 2026
Robert Weir Senior Vice President, Operations & Regulatory Support Exhibit 24.1 - Power of Attorney $3,006,260 Mixed 01 Apr 2026
Chris Crisafulli Senior Vice President, Payor and Industry Strategy Exhibit 24.1 - Power of Attorney $2,087,481 Mixed 01 Apr 2026
Steven D. Cosler Director $1,092,591 +$99,786 +10% Mixed 05 May 2026
Mary Sue Patchett Director $567,573 Mixed 05 May 2026
Randall J. Lewis Director $567,573 Mixed 05 May 2026

Recent insider transactions for Guardian Pharmacy Services, Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Steven D. Cosler GRDN Class A Common Stock Award 16.1% 4,028 29,012 05 May 2026 Direct
Mary Sue Patchett GRDN Class A Common Stock Award 36.5% 4,028 15,071 05 May 2026 Direct
Randall J. Lewis GRDN Class A Common Stock Award 36.5% 4,028 15,071 05 May 2026 Direct
Pharmacy Investors, LLC GRDN Class A Common Stock Options Exercise 136.5% 1,413,939 2,449,867 28 Mar 2026 Direct
Pharmacy Investors, LLC GRDN Class B Common Stock Options Exercise -50% -1,413,939 1,413,939 28 Mar 2026 Direct
William E. Bindley GRDN Class A Common Stock Options Exercise 136.5% 6,100,175 10,569,491 28 Mar 2026 By Bindley Capital Partners I, LLC
William E. Bindley GRDN Class B Common Stock Options Exercise -50% -6,100,175 6,100,175 28 Mar 2026 By Bindley Capital Partners I, LLC
Kendall Forbes GRDN Class A Common Stock Options Exercise 134.3% 608,570 1,061,826 28 Mar 2026 Direct
Kendall Forbes GRDN Class B Common Stock Options Exercise -50% -608,570 608,570 28 Mar 2026 Direct
Cardinal Equity Fund, L.P. GRDN Class A Common Stock Options Exercise 136.5% 471,057 816,180 28 Mar 2026 Direct
Cardinal Equity Fund, L.P. GRDN Class B Common Stock Options Exercise -50% -471,057 471,057 28 Mar 2026 Direct
David K. Morris GRDN Class A Common Stock Options Exercise 252.2% 641,869 896,341 28 Mar 2026 Direct
David K. Morris GRDN Class B Common Stock Options Exercise -50% -641,869 641,870 28 Mar 2026 Direct
Bindley Capital Partners I, LLC GRDN Class A Common Stock Options Exercise 136.5% 6,100,175 10,569,491 28 Mar 2026 Direct
Bindley Capital Partners I, LLC GRDN Class B Common Stock Options Exercise -50% -6,100,175 6,100,175 28 Mar 2026 Direct
Thomas J. Salentine Jr. GRDN Class A Common Stock Options Exercise 136.5% 6,100,175 10,569,491 28 Mar 2026 By Bindley Capital Partners I, LLC
Thomas J. Salentine Jr. GRDN Class B Common Stock Options Exercise -50% -6,100,175 6,100,175 28 Mar 2026 By Bindley Capital Partners I, LLC
John Ackerman GRDN Class A Common Stock Options Exercise 136.5% 471,057 816,180 28 Mar 2026 By Cardinal Equity Fund, L.P.
John Ackerman GRDN Class A Common Stock Options Exercise 136.5% 1,413,939 2,449,867 28 Mar 2026 By Pharmacy Investors, LLC
John Ackerman GRDN Class B Common Stock Options Exercise -50% -471,057 471,057 28 Mar 2026 By Cardinal Equity Fund, L.P.
John Ackerman GRDN Class B Common Stock Options Exercise -50% -1,413,939 1,413,939 28 Mar 2026 By Pharmacy Investors, LLC
Fred Burke GRDN Class A Common Stock Options Exercise 154.6% 1,298,826 2,139,239 28 Mar 2026 Direct
Fred Burke GRDN Class B Common Stock Options Exercise -50% -1,298,826 1,298,825 28 Mar 2026 Direct
Pharmacy Investors, LLC GRDN Class A Common Stock Sale -44.4% $24,566,306 $29.68 -827,636 1,035,928 20 Mar 2026 Direct
David K. Morris GRDN Class A Common Stock Sale -42.5% $5,576,006 $29.68 -187,855 254,472 20 Mar 2026 Direct
Fred Burke GRDN Class A Common Stock Sale -44.4% $19,929,780 $29.68 -671,432 840,413 20 Mar 2026 Direct
Kendall Forbes GRDN Class A Common Stock Sale -43.3% $10,290,092 $29.68 -346,672 453,256 20 Mar 2026 Direct
Cardinal Equity Fund, L.P. GRDN Class A Common Stock Sale -44.4% $8,184,296 $29.68 -275,728 345,123 20 Mar 2026 Direct
Thomas J. Salentine Jr. GRDN Class A Common Stock Sale -44.4% $105,986,620 $29.68 -3,570,677 4,469,316 20 Mar 2026 By Bindley Capital Partners I, LLC
Bindley Capital Partners I, LLC GRDN Class A Common Stock Sale -44.4% $105,986,620 $29.68 -3,570,677 4,469,316 20 Mar 2026 Direct
John Ackerman GRDN Class A Common Stock Sale -44.4% $8,184,296 $29.68 -275,728 345,123 20 Mar 2026 By Cardinal Equity Fund, L.P.
John Ackerman GRDN Class A Common Stock Sale -44.4% $24,566,306 $29.68 -827,636 1,035,928 20 Mar 2026 By Pharmacy Investors, LLC
William E. Bindley GRDN Class A Common Stock Sale -44.4% $105,986,620 $29.68 -3,570,677 4,469,316 20 Mar 2026 By Bindley Capital Partners I, LLC
Kendall Forbes GRDN Class A Common Stock Award 1.13% 8,952 799,928 01 Mar 2026 Direct
David K. Morris GRDN Class A Common Stock Award 2.07% 8,952 442,327 01 Mar 2026 Direct
Fred Burke GRDN Stock Option (right to buy) Award 75,000 75,000 11 Feb 2026 Direct
Kendall Forbes GRDN Stock Option (right to buy) Award 50,000 50,000 11 Feb 2026 Direct
David K. Morris GRDN Stock Option (right to buy) Award 50,000 50,000 11 Feb 2026 Direct
Fred Burke GRDN Class A Common Stock Gift -11.7% -200,000 1,511,845 04 Dec 2025 Direct
Kendall Forbes GRDN Class A Common Stock Gift -2.65% -21,500 790,976 04 Dec 2025 Direct
Steven D. Cosler GRDN Class A Common Stock Purchase 15.6% $99,786 $29.61 3,370 24,984 03 Dec 2025 Direct
John Ackerman GRDN Class A Common Stock Options Exercise 314.5% 471,057 620,851 27 Sep 2025 By Cardinal Equity Fund, L.P.
John Ackerman GRDN Class A Common Stock Options Exercise 314.5% 1,413,940 1,863,564 27 Sep 2025 By Pharmacy Investors, LLC
John Ackerman GRDN Class B Common Stock Options Exercise -33.3% -471,057 942,114 27 Sep 2025 By Cardinal Equity Fund, L.P.
John Ackerman GRDN Class B Common Stock Options Exercise -33.3% -1,413,940 2,827,878 27 Sep 2025 By Pharmacy Investors, LLC
Kendall Forbes GRDN Class A Common Stock Options Exercise 298.5% 608,570 812,476 27 Sep 2025 Direct
Kendall Forbes GRDN Class B Common Stock Options Exercise -33.3% -608,570 1,217,140 27 Sep 2025 Direct
Cardinal Equity Fund, L.P. GRDN Class A Common Stock Options Exercise 314.5% 471,057 620,851 27 Sep 2025 Direct
Cardinal Equity Fund, L.P. GRDN Class B Common Stock Options Exercise -33.3% -471,057 942,114 27 Sep 2025 Direct
Bindley Capital Partners I, LLC GRDN Class A Common Stock Options Exercise 314.5% 6,100,176 8,039,993 27 Sep 2025 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .